Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-18
2006-04-18
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S343000, C514S423000, C540S602000, C544S332000, C546S193000, C546S208000, C546S256000, C546S278400, C546S279100, C548S227000, C548S314700, C548S364100, C548S518000, C548S537000, C548S538000
Reexamination Certificate
active
07030141
ABSTRACT:
The present invention provides compounds of Formula (I):wherein A, B, C, G, and W1have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.
REFERENCES:
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 5807875 (1998-09-01), Rudolf et al.
patent: 23/99018 (2001-02-01), None
patent: WO 95/28420 (1995-10-01), None
patent: WO 97/05161 (1997-02-01), None
patent: WO97/19911 (1997-06-01), None
patent: WO 97/46576 (1997-12-01), None
patent: WO 98/50029 (1998-11-01), None
patent: WO 01/64642 (2001-09-01), None
patent: WO 2001/072705 (2001-10-01), None
patent: WO 2001/074769 (2001-10-01), None
patent: WO 01/96296 (2001-12-01), None
patent: WO 02/08177 (2002-01-01), None
patent: WO 02/24654 (2002-03-01), None
patent: WO 02/30880 (2002-04-01), None
patent: WO 02/48099 (2002-06-01), None
patent: WO 02/057236 (2002-07-01), None
Zhu, B.-Y. et al, Ann. Reports. Med. Chem., vol. 35, 2000, pp. 83-102.
Lapatto et al., Embo. J, 1997:5151-5161.
Mellott et al, Fibrinolysis, 1993: 195-202.
Lynch et al., Thromb. Haemostasis, 1995:640-645.
Schaffer et al., Circulation, 1991: 1741-1748.
Fioravanti et al., Thromb. Res., 1993: 317-324.
Wong et al., Thromb. Res., 1996: 117-126.
Leadley, Curr. Top. Med. Chem., 2001: v. 1, 151-159.
Edmunds et al., Annual Reports in Medicinal Chemistry, 1996:51.
Kunitada and Nagahara, Curr. Pharm. Des., 1996:531-542.
Berge S.M. et al.,Pharmaceutical Salts, Journal of Pharmaceutical Science, 1977;66:1-19.
F Al-Obeidi & Jaostrem: “Factor Xa Inhibitors” Expert Opinion on Therapeutic Patents., vol. 9, No. 7, 1999, pp. 931-953, XP001000512.
Erik Verner et al.: “Development of Serine Protease Inhibitors Displaying a Multicenter Short Hydrogen Bond Binding Mode: Inhibitors of Urokinase-Type Plasminogen Activator and Factor Xa” Journal of Medicinal Chemistry vol. 44, No. 17, 2001, pp. 2753-2771, XP002216503.
Michael R Wiley et al., “Structure-Based Design of Potent, Amidine-Derived Inhibitors of Factor Xa: Evaluation of Selectivity, Anticoagulant Activity, and Antithrombotic Activity” Journal of Medicinal Chemistry, vol. 43, No. 5, 2000, pp. 883-899, XP002186966.
Ying K. Yee et al., “N-Aroylanthranilamide Inhibitors of Human Factor Xa” Journal of Medicinal Chemistry., vol. 43, No. 5, 2000, pp. 873-882, XP002186965.
Bigge Christopher Franklin
Casimiro-Garcia Agustin
Dudley Danette Andrea
Edmunds Jeremy John
Filipski Kevin James
No associations
LandOfFree
Inhibitors of factor Xa and other serine proteases involved... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of factor Xa and other serine proteases involved..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of factor Xa and other serine proteases involved... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3527549